COLUMBIA, Md., July 6 /PRNewswire/ -- Cylex Incorporated, a life sciences company and leader in immune function testing, today announced a supply agreement with Medical & Biological Laboratories Co., Ltd. ("MBL") to distribute Cylex's ImmuKnow(R) assay in the Japanese market. Distribution of ImmuKnow(R) throughout Japan will begin immediately.
Cylex's flagship product, ImmuKnow(R), the first and only FDA-cleared cellular assay for measuring and managing the health of a patient's immune system, has significantly expanded its customer base in the international market. This supply agreement marks ImmuKnow's official distribution entry in the Asian market.
"We are very pleased to establish this relationship with MBL, a leader in the autoimmune, immunology and infectious disease diagnostic markets in Japan," said Tim Ellis, President of Cylex. "ImmuKnow's breakthrough into the Asian market further confirms the acceptance of the assay, not only in the U.S., but on a global level, as well. We look forward to working closely with MBL and to a long and successful relationship."
In addition to the international market, the ImmuKnow(R) assay is currently used in over 50 medical centers in the U.S. ImmuKnow(R) has been integrated into the management of transplant recipients at medical centers that include the University of Pittsburgh, Cleveland Clinic, INTEGRIS Baptist Medical Center in Oklahoma City, Milton Hershey Medical Center, Cedars Sinai, Tampa General and the University of Miami, among others. At INTEGRIS, which is ranked among the top five centers in liver transplant survival, ImmuKnow(R) has been adopted as a standard of care, and improvements in patient outcomes have been well documented. ImmuKnow(R) is also being utilized in widespread research applications.
"We chose the ImmuKnow assay as the best tool available worldwide to better gauge the patient's net state of immunosuppression," said Katsuhiko Nishida, President of MBL. "Patients are known to respond differently to therapeutic drugs, and ImmuKnow provides an effective tool to more precisely individualizing and optimizing immunosuppressive therapy. We are very excited about ImmuKnow's potential contribution to Japanese society and the health of the Japanese people."
About Cylex Incorporated
Cylex is a life science company and a leader in the development and manufacture of unique products that use the immune system for predicting and managing human health. It is the first and only company to offer a patent- protected, FDA-cleared cellular assay of immune system function, ImmuKnow(TM), which measures the vitality of a patient's immune system from a single drop of blood.
The company's products enable physicians to better manage and personalize the treatment of life-threatening diseases, such as HIV, HCV, cancer and autoimmune disorders, as well as solid organ and bone marrow transplantation.
For further information, visit www.cylex.net.
ImmuKnow(R) is currently incorporated into patient protocols at leading U.S. hospitals and clinics. It is the only standardized cellular assay, easily performed in the lab, with quick and accurate results. By optimizing therapy, ImmuKnow(R) helps the physician lower the cost of treatment and improve treatment outcome, reduce the side effects of drugs, and enhance the patient's prospects for long-term quality of life.
Medical and Biological Laboratories Co., Ltd. (MBL), of Japan, is a leading biotechnology company focused on research, development, production and distribution of reagents for the life science marketplace. MBL was established in 1969 and is known as the first manufacturer of antibodies in Japan. The MBL group distributes throughout Japan, Europe and the Americas.
David Kalson, RF|Binder Partners
Kirsten Plonner, RF|Binder Partners
Minoru Yano, Medical & Biological Laboratories Co., Ltd.
TEL: 052 971 2081